Sadia Falcioni
Overview
Explore the profile of Sadia Falcioni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ursi M, Kwiatkowska K, Pirazzini C, Storci G, Messelodi D, Bertuccio S, et al.
Haematologica
. 2024 Oct;
110(2):481-484.
PMID: 39363850
No abstract available.
2.
Malagola M, Polverelli N, Martino M, Patriarca F, Bruno B, Giaccone L, et al.
Transplant Direct
. 2023 Feb;
9(3):e1451.
PMID: 36845852
Methods: With the aim to analyze real-life allogeneic SCTs performed in Italy between 2006 and 2017 in elderly patients (aged >60 y) with acute myeloid leukemia or myelodysplastic syndrome, we...
3.
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, et al.
Transplant Cell Ther
. 2021 Nov;
28(2):96.e1-96.e11.
PMID: 34818581
Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age 70 to 72 years and represents one of the most effective curative treatments for many hematologic...
4.
Galieni P, Travaglini F, Vagnoni D, Ruggieri M, Caraffa P, Bigazzi C, et al.
Br J Haematol
. 2021 Apr;
193(3):542-550.
PMID: 33792026
The Revised International Staging System (R-ISS) stratifies patients affected by Multiple Myeloma (MM) into three distinct risk groups: R-ISS I [ISS Stage I, Standard-Risk cytogenetics and normal Lactase DeHydrogenase (LDH)],...
5.
Pastore D, Bruno B, Carluccio P, De Candia M, Mammoliti S, Borghero C, et al.
Ann Hematol
. 2020 Feb;
99(4):867-875.
PMID: 32036421
A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT....
6.
Vagnoni D, Travaglini F, Pezzoni V, Ruggieri M, Bigazzi C, Dalsass A, et al.
Br J Haematol
. 2015 May;
170(4):523-31.
PMID: 26010293
Detection of circulating plasma cells (PCs) in multiple myeloma (MM) patients is a well-known prognostic factor. We evaluated circulating PCs by flow cytometry (FC) in 104 patients with active MM...
7.
Girmenia C, Raiola A, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al.
Biol Blood Marrow Transplant
. 2014 Mar;
20(6):872-80.
PMID: 24631738
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano...
8.
Dalsass A, Mestichelli F, Ruggieri M, Gaspari P, Pezzoni V, Vagnoni D, et al.
Eur J Haematol
. 2013 Apr;
91(1):10-9.
PMID: 23560441
Deletions of the long arm of chromosome 6 are known to occur at relatively low frequency (3-6%) in chronic lymphocytic leukemia (CLL), and they are more frequently observed in 6q21....
9.
Visani G, Malerba L, Stefani P, Capria S, Galieni P, Gaudio F, et al.
Blood
. 2011 Aug;
118(12):3419-25.
PMID: 21816830
We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of bendamustine (160 mg/m², 180 mg/m², and 200 mg/m² given on days -7 and...
10.
Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, et al.
Eur J Haematol
. 2010 Mar;
84(6):474-83.
PMID: 20331733
Objectives: With the aim to address the issue whether high-dose therapy (HDT) is required after new drugs combinations to improve outcome of elderly newly diagnosed multiple myeloma (MM) patients, we...